Department of Internal Medicine, Cleveland Clinic Florida, Weston, Florida.
Clin Cardiol. 2013 Sep;36(9):542-7. doi: 10.1002/clc.22180. Epub 2013 Aug 8.
Heart failure (HF) is the leading cause of hospitalizations and readmissions in the United States. Approximately one-third of patients admitted for HF are readmitted within 3 months; however, there are few markers that can identify those at highest risk for readmission. The purpose of this study was to identify clinical and laboratory markers associated with hospital readmission in decompensated HF.
Clinical and laboratory markers are associated with readmission rates in decompensated HF.
Clinical and laboratory data from 412 patients admitted with HF were analyzed using a multivariable logistic regression analysis to find predictors of HF readmission by 30 days.
HF readmission rates at 30 days were lowest in those with at least 2 of the following discharge criteria: net fluid reduction >1.3 L (odds ratio [OR]: 0.27, P = 0.019), serum sodium level >135 (OR: 0.46, P = 0.034), and N-terminal brain natriuretic peptide level reduction >23% (OR: 0.11, P = 0.048). In multivariate analysis, those patients meeting ≥2 criteria had a very low risk of 30-day readmission (OR: 0.10, 95% confidence interval: 0.01-0.68, P = 0.019) compared to patients who failed to meet 2 criteria.
A negative fluid balance, normal serum sodium, and net reduction in N-terminal brain natriuretic peptide level during hospitalization may be important indices to target to help reduce the likelihood of HF readmission within 30 days.
心力衰竭(HF)是美国住院和再入院的主要原因。大约三分之一因 HF 入院的患者在 3 个月内再次入院;然而,能够识别那些再入院风险最高的患者的标志物很少。本研究的目的是确定与失代偿性 HF 住院再入院相关的临床和实验室标志物。
临床和实验室标志物与失代偿性 HF 的再入院率相关。
使用多变量逻辑回归分析对 412 例因 HF 入院的患者的临床和实验室数据进行分析,以寻找 30 天 HF 再入院的预测因素。
在符合以下至少 2 项出院标准的患者中,30 天 HF 再入院率最低:净液体减少量>1.3 L(比值比 [OR]:0.27,P = 0.019)、血清钠水平>135(OR:0.46,P = 0.034)和 N-末端脑钠肽水平降低>23%(OR:0.11,P = 0.048)。多变量分析显示,符合≥2 项标准的患者 30 天再入院的风险非常低(OR:0.10,95%置信区间:0.01-0.68,P = 0.019),而不符合 2 项标准的患者再入院风险较高。
住院期间负液体平衡、正常血清钠和 N-末端脑钠肽水平的净降低可能是重要的指标,有助于降低 30 天内 HF 再入院的可能性。